Delayed Recovery of Normal Hematopoiesis in Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia: A Comparison to All-trans Retinoic Acid Treatment

• SHINJO Kaori

  Department of Internal Medicine III, Hamamatsu University School of Medicine

• TAKESHITA Akihiro

  Laboratory Medicine, Hamamatsu University School of Medicine

• SAHARA Naohi

  Department of Internal Medicine III, Hamamatsu University School of Medicine

• KOBAYASHI Miki

  Department of Internal Medicine III, Hamamatsu University School of Medicine

• NAKAMURA Satoki

  Department of Internal Medicine III, Hamamatsu University School of Medicine

• SHIGENO Kazuyuki

  Department of Internal Medicine III, Hamamatsu University School of Medicine

• NAITO Kensuke

  Department of Internal Medicine III, Hamamatsu University School of Medicine

• MAEKAWA Masato

  Laboratory Medicine, Hamamatsu University School of Medicine

• OHNISHI Kazunori

  Department of Internal Medicine III, Hamamatsu University School of Medicine

• OHNO Ryuzo

  Aichi Cancer Center, Nagoya

抄録

Objective To examine laboratory data including total blood cell count, leukocyte morphology and coagulation parameters during treatment for acute promyelocytic leukemia (APL) at a single institute, and compare the precise differences between all-trans retinoic acid (ATRA) and arsenic trioxide (As₂O₃) treatment.<br>Patients and Methods Sixteen patients with APL who were treated with ATRA or As₂O₃ alone and achieved complete remission (CR) were analyzed. ATRA 45 mg/m²/day was given orally until CR. As₂O₃ 0.15 mg/kg/day was given intravenously until leukemic blasts and promyelocytes were eliminated from the bone marrow.<br>Results All 7 patients in the ATRA-treated group were primary cases and all 9 patients in the As₂O₃-treated group were relapsed cases after the achievement of CR with the ATRA. There was no difference in the data before treatment between these two groups. The duration of leukocytopenia and neutropenia during As₂O₃ treatment was significantly longer than those of ATRA treatment. The nadir of leukocyte and neutrophil counts was observed later in the As₂O₃-treated group. Terminal neutrophil differentiation was observed more obviously in the ATRA-treated group. The red blood cell count and hemoglobin concentration decreased significantly at the end of As₂O₃ treatment and were lower than those of ATRA treatment. Platelets recovered earlier in the ATRA-treated group. Coagulation parameters were not significantly changed between the two groups.<br>Conclusion In comparison with ATRA treatment, the recovery of several components in the peripheral blood cells was delayed in As₂O₃ treatment. Therefore we should pay more and longer attention in As₂O₃ treatment.

収録刊行物

• Internal Medicine

  Internal Medicine 44 (8), 818-824, 2005

  一般社団法人 日本内科学会

キーワード

• laboratory data
• acute promyelocytic leukemia
• all-<i>trans</i> retinoic acid
• arsenic trioxide

詳細情報

• CRID: 1390001204869718656
• NII論文ID: 130000076342
• NII書誌ID: AA10827774
• DOI: 10.2169/internalmedicine.44.818
• ISSN: 13497235
• ISSN: 09182918
• NDL書誌ID: 7402129
• PubMed: 16157979
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I7402129
• Web Site: http://www.jstage.jst.go.jp/article/internalmedicine/44/8/44_8_818/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2006293447
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可